<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">527</article-id><article-id pub-id-type="doi">10.17816/ACEN.2018.2.6</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experimental evaluation of bioequivalenceт of the original and generic peptide drugs in multiple sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Экспериментальная оценка биоэквивалентности оригинальных и воспроизведенных пептидных препаратов при рассеянном склерозе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ryabtseva</surname><given-names>Marya S.</given-names></name><name xml:lang="ru"><surname>Рябцева</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>infantes@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Neugodova</surname><given-names>Natalya P.</given-names></name><name xml:lang="ru"><surname>Неугодова</surname><given-names>Наталья П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>infantes@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Batuashvili</surname><given-names>Tamara A.</given-names></name><name xml:lang="ru"><surname>Батуашвили</surname><given-names>Тамара А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>infantes@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Simutenko</surname><given-names>Ludmila V.</given-names></name><name xml:lang="ru"><surname>Симутенко</surname><given-names>Людмила В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>infantes@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Scientific Centre for Expert Evaluation of Medical Products</institution></aff><aff><institution xml:lang="ru">ФГБУ «Научный центр экспертизы средств медицинского применения»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-08-08" publication-format="electronic"><day>08</day><month>08</month><year>2018</year></pub-date><volume>12</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>39</fpage><lpage>44</lpage><history><date date-type="received" iso-8601-date="2018-08-09"><day>09</day><month>08</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Ryabtseva M.S., Neugodova N.P., Batuashvili T.A., Simutenko L.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Ryabtseva M.S., Neugodova N.P., Batuashvili T.A., Simutenko L.V.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Ryabtseva M.S., Neugodova N.P., Batuashvili T.A., Simutenko L.V.</copyright-holder><copyright-holder xml:lang="ru">Ryabtseva M.S., Neugodova N.P., Batuashvili T.A., Simutenko L.V.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/527">https://annaly-nevrologii.com/pathID/article/view/527</self-uri><abstract xml:lang="en"><p>Multiple sclerosis is a chronic, widespread neurodegenerative disease, which is accompanied by a considerable degree of disability and requires lifelong drug therapy. In this regard, the relevant objective for the production of generic drugs for treating multiple sclerosis, so-called generics, is to ensure their quality to be at the level of the original forms. This article provides an overview of methods for determining the comparability of generics and original drugs for major groups of medications used in the treatment of multiple sclerosis: glatiramer acetate preparations, mitoxantrone, monoclonal antibodies, immunomodulating agents, and preparations based on interferon-β. Experimental allergic encephalomyelitis, a standard model for verifying specific activity of glatiramer acetate preparations, was used as an example to analyze factors that impair the consistent assessment of generics. Approaches to standardization of methods for monitoring the effectiveness of medications of this group were suggested.</p></abstract><trans-abstract xml:lang="ru"><p>Рассеянный склероз – широко распространенное хроническое нейродегенеративное заболевание, которое сопровождается значительной степенью инвалидизации и требует пожизненной лекарственной терапии. В связи с этим при производстве воспроизведенных лекарственных препаратов для лечения рассеянного склероза, так называемых дженериков, актуальной задачей является обеспечение их качества на уровне оригинальных форм.</p> <p>В статье представлен обзор мтодов определения сопоставимости дженериков и оригинальных препаратов для основных групп лекарственных средств, используемых для лечения рассеянного склероза: препаратов глатирамера ацетата, митоксантрона, моноклональных антител, иммуномодулирующих препаратов, препаратов на основе интерферона-β. На примере экспериментального аллергического энцефаломиелита, используемого для подтверждения специфической активности препаратов глатирамера ацетата, проведен анализ факторов, мешающих корректной оценке дженериков. Предложены подходы к стандартизации методов контроля эффективности препаратов данной группы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>generics</kwd><kwd>effectiveness</kwd><kwd>glatiramer acetate</kwd><kwd>experimental allergic encephalomyelitis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>воспроизведенные лекарственные средства</kwd><kwd>эффективность</kwd><kwd>глатирамера ацетат</kwd><kwd>экспериментальный аллергический энцефаломиелит</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Buzzard K.A., Broadley S.A., Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol. Sci 2012; 13(10): 12665-12709. DOI: 10.3390/ijms131012665. PMID: 23202920.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kuzina E.S. Ubiquitin-independent proteolysis of the main myelin protein and its role in the development of experimental autoimmune encephalomyelitis. dis. ... cand. chem. science. Moscow; 2015. 113 p. http://www.chem.msu.ru/rus/theses/2015/2015-02-26-kuzina/fulltext.pdf. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Кузина Е.С. Убиквитин-независимый протеолиз основного белка миелина и его роль в развитии экспериментального аутоиммунного энцефаломиелита: дис. … канд. хим. наук. М., 2015. 113 с. http://www.chem.msu.ru/rus/theses/2015/2015-02-26-kuzina/fulltext.pdf.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Teitelbaum D., Aharoni R., Sela M., Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 1991; 88(21): 9528-9532. DOI: 10.1073/pnas.88.21.9528. PMID: 1719533.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Betaferon. http://www.rlsnet.ru/tn_index_id_6393.htm (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Бетаферон. http://www.rlsnet.ru/tn_index_id_6393.htm</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Buttmann M., Rieckmann P. Interferon-beta1b in multiple sclerosis. Exp Rev Neurotherapeutics 2007; 7(3): 227–239. DOI: 10.1586/14737175.7.3.227. PMID: 17341170.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kovarik P., Sauer I., Schaljo B. Molecular mechanisms of the anti-inflammatory functions of interferons. Immunobiology 2007; 212 (9–10): 895–901. DOI: 10.1016/j.imbio.2007.09.011. PMID: 18086388.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Feng X., Yau D., Holbrook C., Reder A.T. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 2002; 22(3): 311–319. DOI: 10.1089/107999002753675730. PMID: 12034038.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hartung H.P., Gonsette R., König N. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360 (9350): 2018–2025. DOI: 10.1016/S0140-6736(02)12023-X. PMID: 12504397.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Rituximab. http://www.rlsnet.ru/mnn_index_id_2695.htm. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Ритуксимаб. http://www.rlsnet.ru/mnn_index_id_2695.htm.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Cross A.H., Stark J.L., Lauber J. et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180(1–2): 63–70. DOI: 10.1016/j.jneuroim.2006.06.029. PMID: 16904756.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ransohoff R.M. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356(25): 2622–2629. DOI: 10.1056/NEJMct071462. PMID: 17582072.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tanasescu R., Ionete C., Chou I.J., Constantinescu C.S. Advances in the treatment of relapsing-remitting multiple sclerosis. Biomed J 2014; 37(2): 41–49. DOI: 10.4103/2319-4170.130440. PMID: 24732658.</mixed-citation></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Milikhina N.V. The study of the humoral link of specific immunity in the experimental model of multiple sclerosis - allergic encephalomyelitis. In: Scientific community of students of the XXI century. Natural Sciences. Materials of the XXIX International Stud. Sci. and Pract. Conference. Novosibirsk; 2015: 3(28): 18–24. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Милихина Н.В. Изучение гуморального звена специфического имунитета при экспериментальной модели рассеянного склероза – аллергического энцефаломиелита. В сб.: Научное сообщество студентов XXI столетия. Естественные науки. Матер. XXIX междунар. студ. науч.-практ. конф. Новосибирск, 2015; 3(28): 18–24.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Zavalishin I.A., Eliseeva D.D. Pathogenetic therapy of multiple sclerosis Lech Vrach 2009; (9): 43–46. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Завалишин И.А., Елисеева Д.Д. Патогенетическая терапия рассеянного склероза Лечащий врач 2009; (9): 43–46.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Gusev E.I., Demina T.L., Khachanova N.V. Comparative analysis of beta-interferons used for the treatment of multiple sclerosis. Neyroimmunologiya 2003; (1): 45–50. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Гусев Е.И., Демина Т.Л., Хачанова Н.В. Сравнительный анализ бета-интерферонов, используемых для лечения рассеянного склероза. Нейроиммунология 2003; (1): 45–50.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Copaxone prescribing information https://www.copaxone.com/Resources/pdfs/PrescribingInformation.pdf</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Adamus G., Amundson D., Vainiene M. et al. Myelin basic protein specific T-helper cells induce experimental anterior uveitis. J Neurosci Res 1996; 44(6): 513–518. DOI: 10.1002/(SICI)1097-4547(19960615)44:6&lt;513::AID-JNR1&gt;3.0.CO;2-E. PMID: 8794942.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Hernández-Pedro N.Y., Espinosa-Ramirez G., de la Cruz V.P. et al. Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol 2013; 2013: 413465. DOI: 10.1155/2013/413465. PMID: 24174969.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tsunoda I., Fujinami R.S. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler’s murine encephalomyelitis virus. J Neuropathol Exp Neurol 1996; 55(6): 673–686. DOI: 10.1097/00005072-199606000-00001 . PMID: 8642393.</mixed-citation></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Pivneva T.A. Mechanisms of demyelination in multiple sclerosis. Neyrofiziologiya 2009; 41(5): 429–437. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Пивнева Т.А. Механизмы демиелинизации при рассеянном склерозе. Нейрофизиология 2009; 41(5): 429–437.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>Baker D., Jackson S.J. Models of multiple sclerosis. ACNR 2007; 6: 10-12. http://www.acnr.co.uk/JF07/ACNR_JF07_review_model.pdf</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dal Canto M.C., Melvold R.W., Kim B.S., Miller S.D. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech 1995; 32(3): 215–229. DOI: 10.1002/jemt.1070320305. PMID: 8527856.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Marques A., Müller S. Mouse models of autoimmune diseases. Current Drug Discov Technol 2009; 6(4): 262–269. DOI: 10.2174/157016309789869047 PMID: 20025594.</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Karkishchenko N.N., Gracheva S.V. (ed.) Guidance on laboratory animals and alternative models in biomedical research. Мoscow: Profile-2С; 2010. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Каркищенко Н.Н., Грачева С.В. (ред.) Руководство по лабораторным животным и альтернативным моделям в биомедицинских исследованиях. М.: Профиль-2С; 2010.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
